Health
Secukinumab Has High Retention Rate in Real-World Psoriatic Arthritis Study – AJMC.com Managed Markets Network
New real-world data shows 64% of patients with psoriatic arthritis who had previously been on a biologic stayed on secukinumab for the duration of the study.
A new study suggests secukinumab (Cosenytx) has a high retention rate among biologic-experienced patients with psoriatic arthritis (PsA) in real-world settings, and also produces minimal serious side effects.
The research is important because previous data on the real-world usage of the recombinant human monoclonal antibody has been scarce. The drug, which targets interleukin-17A, has been approved for the treatment of PsA since 2015 in Europe and 2016 in the United States.
A team of Greek inv…
-
Noosa News19 hours agoBrisbane’s original 1979 electric trains take one last journey
-
General24 hours agoNRL live updates: Canberra Raiders vs St George Illawarra Dragons, North Queensland Cowboys vs Melbourne Storm
-
General24 hours agoWA road toll hits decade high as five people killed in 24 hours
-
General18 hours agoParis opens River Seine for public swimming for first time since 1923